Prolytix Enhances Thrombosis and Hemostasis Testing Capabilities
Prolytix, a U.S. leader in bioanalytical and protein characterization services, announced it has expanded its thrombosis and hemostasis testing offerings through the acquisition of 60 validated assays from the Hemostasis…
Prolytix Honored as One of Vermont’s Best Places to Work 2025
Prolytix Honored as One of Vermont’s Best Places to Work 2025 Prolytix is excited to announce that we have been recognized as one of Vermont’s Best Places to Work 2025…
Allumiqs and Prolytix form strategic partnership to accelerate drug discovery and development
The partnership focuses on enabling customer success, by reducing time-to-value and optimizing R&D investments with integrated solutions and processes. Halifax, NS and Essex Junction, VT, March 11, 2024 – Allumiqs…
Haematologic Technologies Is Now Prolytix, Integrating to Support Growing Large Molecule Market
ESSEX JUNCTION, VT; March 3, 2022 – Haematologic Technologies (“HT”), a global analytical and bioanalytical leader for large molecule drug development, today announced they’ll be operating under the new name,…